Cullen/Frost Bankers, Inc. Argenx Se Call Options Transaction History
Cullen/Frost Bankers, Inc.
- $7.23 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ARGX
# of Institutions
400Shares Held
30.9MCall Options Held
376KPut Options Held
489K-
Price T Rowe Associates Inc Baltimore, MD5.82MShares$3.28 Billion0.36% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.51MShares$1.98 Billion2.99% of portfolio
-
Janus Henderson Group PLC London, X02.48MShares$1.4 Billion0.72% of portfolio
-
Capital World Investors Los Angeles, CA1.7MShares$959 Million0.15% of portfolio
-
Avoro Capital Advisors LLC New York, NY1.24MShares$699 Million10.11% of portfolio
About ARGENX SE
- Ticker ARGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,323,800
- Market Cap $31.2B
- Description
- argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...